Multicenter phase 3 trial of first-line bevacizumab plus atezolizumab and chemotherapy for extensive-stage small cell lung cancer

The phase 3 BEAT-SC trial, in Japan and China, evaluated the efficacy and safety of adding bevacizumab to first-line atezolizumab plus platinum-based chemotherapy (carboplatin/cisplatin and etoposide, ACE) for extensive-stage small cell lung cancer (ES-SCLC). Patients were randomized 1:1 to bevacizumab+ACE (bevacizumab arm; n=167) or placebo+ACE (placebo arm; n=166). The primary endpoint was investigator-assessed progression-free survival (PFS). Median investigator-assessed PFS was 5.7 months in the bevacizumab arm and 4.4 months in the placebo arm (HR 0.70; p=0.0060). At the first interim analysis of overall survival (OS), there was no significant difference between arms (HR 1.22; p=0.2212). Grade 3-4 treatment-related adverse events occurred in 85.5% and 86.0% of patients in the bevacizumab arm and placebo arm, respectively, whereas grade 5 TRAEs occurred in 3.0% and 4.9%. The authors conclude that BEAT-SC met its primary PFS endpoint; OS data were immature. Bevacizumab plus ACE was generally well tolerated.